Barclays
DFTX

Barclays’s Definium Therapeutics DFTX Stock Holding History

Barclays’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$750K Sell
39,683
-143,940
-78% -$2.44M ﹤0.01% 2933
2025
Q4 		$2.46M Buy
183,623
+33,018
+22% +$409K ﹤0.01% 2783
2025
Q3 		$1.78M Sell
150,605
-24,628
-14% -$230K ﹤0.01% 2964
2025
Q2 		$1.14M Buy
175,233
+55,660
+47% +$366K ﹤0.01% 3253
2025
Q1 		$700K Sell
119,573
-35,861
-23% -$257K ﹤0.01% 3315
2024
Q4 		$1.08M Buy
155,434
+19,336
+14% +$133K ﹤0.01% 3329
2024
Q3 		$774K Buy
136,098
+91,271
+204% +$635K ﹤0.01% 3523
2024
Q2 		$323K Buy
44,827
+35,680
+390% +$312K ﹤0.01% 3304
2024
Q1 		$86K Hold
9,147
– – ﹤0.01% 4484
2023
Q4 		$33.5K Hold
9,147
– – ﹤0.01% 4823
2023
Q3 		$28.6K Hold
9,147
– – ﹤0.01% 4073
2023
Q2 		$32.7K Hold
9,147
– – ﹤0.01% 4010
2023
Q1 		$29K Hold
9,147
– – ﹤0.01% 4581
2022
Q4 		$20.1K Sell
9,147
-78
-0.8% -$217 ﹤0.01% 4811
2022
Q3 		$32K Buy
9,225
+7,705
+507% +$74K ﹤0.01% 3915
2022
Q2 		$15K Sell
1,520
-1,965
-56% -$24.9K ﹤0.01% 4502
2022
Q1 		$58K Buy
+3,485
New +$60.5K ﹤0.01% 4055

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barclays's DFTX Position: Q1 2026 in Review

Barclays reduced its Definium Therapeutics (DFTX) stake by 78% in Q1 2026, selling an estimated $2.44M and leaving 39,683 shares worth $750K. The position accounts for ﹤0.01% of the portfolio, ranked #2933.

Barclays first reported a position in DFTX in Q1 2022 and has held it in 17 quarters since. The position peaked at $2.46M in Q4 2025. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Barclays held 39,683 shares of Definium Therapeutics worth $750K as of Q1 2026.
  • Barclays sold 143,940 Definium Therapeutics shares in Q1 2026, an estimated $2.44M.
  • Definium Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2933 holding.
  • Barclays first reported a position in Definium Therapeutics in Q1 2022 and has held it in 17 quarters since.
  • Barclays's Definium Therapeutics position peaked at $2.46M in Q4 2025.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.